Henlius debut : investement 1.4 billion in r&d cause losses to expand，product commercialization
In 2019, the operating income of Henlius is about CNY 90.9 million, with a year-on-year growth of over 11 times. The year's cumulative r&d investment was about CNY 1.407 billion, up 44.36% year on year. As a result of continuous research and development investment, the total profit loss of the current period widened to CNY 876 million. In 2019, the sales and distribution expenditure of Fenlius was about CNY 45.7 million, mainly due to the plan to build a commercial operation team ahead of the launch and sales of Trastuzumab in 2020.